Oct 22, 2019 - Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
Oct 17, 2019 - Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.
Oct 17, 2019 - Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Oct 16, 2019 - Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oct 15, 2019 - These aren't the highest payouts in the industry, but they have the best chance to steadily climb.
Oct 14, 2019 - Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.
Oct 11, 2019 - FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
Oct 10, 2019 - Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.
Oct 10, 2019 - J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.
Oct 09, 2019 - Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.